Non Hodgkin Lymphoma Clinical Trial
Radiation Therapy and High-Dose Corticosteroids in Treating Older Patients With Primary CNS Non-Hodgkin’s Lymphoma
Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with a corticosteroid, such as dexamethasone, may be an effective treatment for non-Hodgkin's lymphoma.
PURPOSE: Phase II trial to study the effectiveness of radiation therapy and high-dose dexamethasone in treating older patients with primary CNS non-Hodgkin's lymphoma.
Full Description
OBJECTIVES:
Assess the effectiveness of high-dose dexamethasone after whole-brain radiotherapy in maintaining response and preventing recurrence in elderly patients with primary central nervous system non-Hodgkin's lymphoma.
Assess the toxic effects of this regimen in these patients.
Assess the survival rate of patients after this regimen.
Identify the anatomic rates of recurrence and frequency of systemic involvement in patients treated with this regimen.
Identify the factors that appear to be associated with outcome in patients treated with this regimen.
OUTLINE: Patients undergo whole-brain radiotherapy (WBRT) daily 5 days a week for 4.5 weeks. Beginning 30 days after WBRT is completed, patients receive high-dose dexamethasone IV on days 1-5 during course 1 and on day 1 only during all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients are followed at 1 month after radiotherapy, every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 28 patients will be accrued for this study within 6 years.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Pathologically confirmed non-Hodgkin's lymphoma with intracranial lesions
Intraocular lymphoma eligible, if not sole site of disease
No occult systemic lymphoma
Measurable or evaluable disease by CT scan or MRI
No neoplastic meningitis or gross spinal cord involvement
PATIENT CHARACTERISTICS:
Age:
70 and over
Performance status:
ECOG 0-3
Other:
No prior history of lymphoma
No other active malignancy except basal cell skin cancer or carcinoma in situ of the cervix
HIV negative
No active peptic ulcer disease
No uncontrolled diabetes mellitus
No active pancreatitis
No active bleeding
No poorly controlled major psychiatric illness
No serious uncontrolled infection
PRIOR CONCURRENT THERAPY:
Biologic therapy:
No prior bone marrow transplantation
Chemotherapy:
No prior chemotherapy
Radiotherapy:
No prior radiotherapy to the brain or head and neck region
Surgery:
No prior transplantations (renal, hepatic, or cardiac)
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 14 Locations for this study
Scottsdale Arizona, 85259, United States
Jacksonville Florida, 32224, United States
Peoria Illinois, 61602, United States
Urbana Illinois, 61801, United States
Cedar Rapids Iowa, 52403, United States
Des Moines Iowa, 50309, United States
Sioux City Iowa, 51101, United States
Wichita Kansas, 67214, United States
Rochester Minnesota, 55905, United States
Saint Cloud Minnesota, 56303, United States
Bismarck North Dakota, 58501, United States
Rapid City South Dakota, 57709, United States
Sioux Falls South Dakota, 57104, United States
Regina Saskatchewan, S4T 7, Canada
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.